Showing results (111-120 of 138) with videos related to
Sort By:
Pageof 14
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 3, 2020
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M MutationYuankai Shi, Shucai Zhang, Xingsheng Hu, et al.Thoracic Cancer|September 29, 2018
Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study)Yan Xu, Li Zhang, Jian Fang, et al.Thoracic Cancer|May 17, 2022
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional studyBo Zhang, Xingya Li, Zhiyong Ma, et al.Therapeutic Advances in Medical Oncology|November 25, 2022
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)Shun Lu, Ying Cheng, Jianying Zhou, et al.Plos One|November 25, 2015
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective StudyXingsheng Hu, Li Zhang, Yuankai Shi, et al.Lung Cancer (Amsterdam, Netherlands)|September 28, 2014
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Xingsheng Hu, Baohui Han, Aiqin Gu, et al.The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE TrialXi Li, Li Zhang, Da Jiang, et al.Pageof 14